MMP-7 promoter polymorphisms do not influence CD4+ recovery and changes in plasma viral load during antiretroviral therapy for HIV-1 infection.
Matrix metalloproteinase-7 (MMP-7) generates soluble Fas Ligand (FasL), which is involved in the apoptotic loss of CD4+ T cells during HIV infection. We evaluated whether two polymorphisms in MMP-7 promoter could influence CD4+ recover in response to antiretroviral therapy, and found that these polymorphisms are ineffective.
Lugli
E
E
Department of Biomedical Sciences, Chair of Immunology, University of Modena and Reggio Emilia, 41100 Modena, Italy.
Pinti
M
M
Nasi
M
M
Troiano
L
L
Prada
N
N
Mussini
C
C
Borghi
V
V
Esposito
R
R
Cossarizza
A
A
D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count / Q000379:methods; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000821:virology; D015658:HIV Infections / Q000235:genetics / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008297:Male; D020783:Matrix Metalloproteinase 7; D008666:Metalloendopeptidases / Q000235:genetics / Q000276:immunology*; D008875:Middle Aged; D011110:Polymorphism, Genetic / Q000235:genetics / Q000276:immunology*; D019562:Viral Load / Q000379:methods
D044966:Anti-Retroviral Agents; D008666:Metalloendopeptidases; C060932:MMP7 protein, human; D020783:Matrix Metalloproteinase 7